News from emd serono A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 30, 2019, 09:02 ET EMD Serono Makes Multiple Sclerosis Visible This World MS Day and Beyond

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, joins the global multiple sclerosis (MS)...


May 28, 2019, 13:53 ET EMD Serono to Present Data at CMSC Annual Meeting Showcasing Breadth of MS Portfolio and Commitment to Understanding How MS Impacts Patients

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, will present data from its multiple sclerosis...


May 14, 2019, 19:44 ET FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma

BAVENCIO is the first anti-PD-L1 in combination with INLYTA approved by FDA for first-line treatment of patients with advanced renal cell carcinoma...


May 10, 2019, 13:46 ET Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton's Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced new 48-week results of the...


May 07, 2019, 08:00 ET EMD Serono Launches MS-LINK™, a Community to Advance MS Science and Improve Patient Lives

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the launch of MS-LINK™...


Apr 30, 2019, 08:08 ET EMD Serono to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that data from across its...


Apr 08, 2019, 14:03 ET MAVENCLAD® (Cladribine) Tablets Now Covered by Express Scripts

EMD Serono, Inc. today announced that Express Scripts is covering on its formulary the oral multiple sclerosis (MS) therapy, MAVENCLAD® (cladribine)...


Mar 29, 2019, 19:55 ET FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that the U.S. Food and Drug...


Feb 28, 2019, 14:17 ET EMD Serono to Present Multiple Sclerosis Data on Cladribine Tablets and Evobrutinib at ACTRIMS 2019

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, will present data at the fourth annual ACTRIMS...


Feb 11, 2019, 17:44 ET FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that...


Feb 04, 2019, 09:15 ET Elizabeth Varki Jobes, Esq. Joins EMD Serono as Chief Compliance Officer North America

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, today announced that Elizabeth Varki Jobes, Esq. ...


Nov 07, 2018, 09:00 ET EMD Serono and American Cancer Society Collaborate to Support Needs of Cancer Caregivers

Embracing Carers™, the global initiative designed to increase awareness, discussion, and action about the often-overlooked needs of caregivers,...


Oct 31, 2018, 09:00 ET EMD Serono Launches Community-Based Program to Advance Understanding of the Impact of Multiple Sclerosis on Patients and Caregivers

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announces the launch of MS On My Mind (MSOMM),...


Oct 25, 2018, 09:00 ET EMD Serono and Can Do MS Deliver Educational Programs and Support Groups to Multiple Sclerosis Caregivers

Embracing Carers™, the global initiative designed to increase awareness and action about the often-overlooked needs of caregivers, today announced a...


Oct 11, 2018, 13:43 ET Global Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the publication of results from ...


Aug 31, 2018, 08:00 ET Rehan Verjee to Lead EMD Serono as Company Advances its Innovative Medicines Strategy in North America

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, today announced that Rehan Verjee has been...


Jul 30, 2018, 06:00 ET FDA Accepts File for Cladribine Tablets as Potential Treatment for Relapsing Forms of Multiple Sclerosis

Cladribine tablets is an investigational oral therapy with proposed dosing of a maximum of 20 days over two years with no additional dosing required...


Jun 25, 2018, 09:01 ET Caregiver Action Network Launches Family Caregiver ECHO® to Provide Family Caregivers in Medically Underserved Areas with Interactive Online Mentoring and Support

Caregiver Action Network (CAN) announced today the launch of Family Caregiver ECHO®, a new program that will provide family caregivers in globally...


May 29, 2018, 09:00 ET EMD Serono to Present MS Data and Debut New Patient Resources at CMSC 2018

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that six abstracts including...


Apr 30, 2018, 12:28 ET 14th Annual EMD Serono Specialty Digest™ Educates Health Plans on Latest Trends in Unmet Payer Needs and Patient-Centric Services

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the launch of the 14th edition...


Apr 23, 2018, 09:26 ET EMD Serono R&D Building Earns First WELL Gold Certification™ in U.S. for New & Existing Building Project

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, today announced that its R&D facility's Sagamore ...


Apr 13, 2018, 12:06 ET EMD Serono Highlights Commitment to Advance Multiple Sclerosis Treatment with Investigational Cladribine Tablets and Rebif® Data at AAN 2018

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, today announced data for Cladribine Tablets, an...


Mar 06, 2018, 09:21 ET Wendy Sussman Joins EMD Serono as Vice President of U.S. Healthcare Government & Public Affairs

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, today announced that Wendy Sussman has joined...


Feb 01, 2018, 08:30 ET EMD Serono to Present Data Highlighting Investigational Cladribine Tablets at ACTRIMS 2018

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, today announced that six posters evaluating...


Dec 07, 2017, 07:00 ET John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced the appointment of John Walsh, M.D....